AIM ImmunoTech to Present at the Virtual Investor Long COVID Event
OCALA, Fla., Sept. 21, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that it will participate in the Virtual Investor Long COVID Event on Wednesday, September 28, 2022 at 3:00 PM ET.
Related news for (AIM)
- AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market
- AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
- AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
- AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director